• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Life sciences >The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the 'clinically non-functioning' pituitary adenomas in vitro
【24h】

The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the 'clinically non-functioning' pituitary adenomas in vitro

机译：选择性sst1，sst2，sst5生长抑素受体激动剂，生长抑素/多巴胺（SST / DA）嵌合体和溴隐亭对“临床无功能”垂体腺瘤的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aim of the work was to investigate the effects of somatostatin analogs acting selectively on sst1 (BIM-23926), sst2 (BIM-23120) and sst5 (BIM-23206) receptor subtypes on the viability of "clinically non-functioning" pituitary adenomas in vitro. The effects of native SST (SST-14), a SST/DA chimera (BIM-23A387) and a D-2-dopamine receptor agonist bromocriptine (BC) were also examined. The study was performed on 10 surgically removed pituitary macroadenomas, diagnosed before surgery as "non-functioning". A part of each tumor was mechanically dispersed and digested with collagenase to isolate the tumoral cells. Another part of each tumor was fixed, embedded in paraffin and immunostained to reveal the pituitary hormones and SST receptor subtypes (sstl, sst2A, sst2B, sst3, sst4, sst5). The tumoral cell suspensions were incubated for 24 It with the substances mentioned above. The quantity of viable cells was estimated using the EZ4U system. The results were compared with the immunohistochemical evaluation of the hormonal profile of adenoma and the sst receptor subtype immunoreactivities present. The findings indicate that selective sstl, sst2 and sst5 receptors agonists, SST/DA chimera and D-2-dopamine receptor agonist bromocriptine affect the viability of some, but not all, "clinically non-functioning" pituitary adenomas in vitro. The most effective was bromocriptine. The investigated somatostatin analogs including SST/DA chimera exerted roughly similar inhibitory effects. Further studies are needed to fully evaluate the potential usefulness of these compounds in the pharmacological treatment of "non-functioning" pituitary tumors. (c) 2005 Elsevier Inc. All rights reserved.
机译：这项工作的目的是研究生长抑素类似物选择性作用于sst1（BIM-23926），sst2（BIM-23120）和sst5（BIM-23206）受体亚型对“临床无功能”垂体腺瘤生存力的影响。体外。还检查了天然SST（SST-14），SST / DA嵌合体（BIM-23A387）和D-2-多巴胺受体激动剂溴隐亭（BC）的作用。该研究是对10例手术切除的垂体大腺瘤进行的，在手术前被诊断为“无功能”。机械地分散每个肿瘤的一部分并用胶原酶消化以分离肿瘤细胞。每个肿瘤的另一部分被固定，包埋在石蜡中并进行免疫染色以揭示垂体激素和SST受体亚型（sstl，sst2A，sst2B，sst3，sst4，sst5）。将肿瘤细胞悬浮液与上述物质孵育24It。使用EZ4U系统估算了活细胞的数量。将结果与腺瘤的荷尔蒙特征和所存在的sst受体亚型免疫反应性的免疫组织化学评估相比较。这些发现表明选择性的sstl，sst2和sst5受体激动剂，SST / DA嵌合体和D-2-多巴胺受体激动剂溴隐亭在体外影响某些但不是全部“临床无功能”的垂体腺瘤的生存能力。最有效的是溴隐亭。研究的生长抑素类似物（包括SST / DA嵌合体）发挥了大致相似的抑制作用。为了进一步评估这些化合物在“非功能性”垂体瘤的药物治疗中的潜在效用，还需要进一步的研究。 （c）2005 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号